TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10027031
Drug: Ketamine bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine bolus, 0.75 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.75; n = 12)
Study: 10027031
Drug: Ketamine bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine bolus, 0.25 mg i.v. followed by propofol infusion, 30 mg.kg‐1.h‐1 (Group PK0.25; n = 12)
Study: 7717488
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg-1
Study: 7717488
Drug: Ketamine/midazolam 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine/midazolam 2 mg.kg-1 after midazolam pretreatment
Study: 7717488
Drug: Ketamine/esmolol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine/esmolol 2 mg.kg-1 with esmolol
Study: 2030491
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized P4 supplementation (200 mg four times daily)
Study: 24379596
Drug: Perirenal space
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perirenal space blocking (PSB) + specialized medical therapy (SMT)
Study: 24379596
Drug: No perirenal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perirenal space blocking (NPSB) + specialized medical therapy (SMT)
Study: 16931991
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous morphine
Study: 11893342
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of epoetin (recombinant human erythropoietin)
Study: 11893342
Drug: Minimal reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal reduction (10%) in epoetin dose
Study: 9810889
Drug: Elase ointment
Normalized name: ELASE OINT
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elase ointment (proteolytic ointment)
Study: 9810889
Drug: Placebo (ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ointment vehicle)
Study: 9810889
Drug: Complete ointment
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete ointment (Elase)
Study: 2494014
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion containing medium‐chain triacylglycerols (MCT) and long‐chain triacylglycerols (LCT)
Study: 836112
Drug: 125 IU
Normalized name: Calcium/Vitamin D 200 MG-125 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 IU of human chorionic gonadotropin (HCG) intramuscularly daily for 30 days
Study: 20840349
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50mg twice weekly (BIW)
Study: 20840349
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50mg weekly (QW)
Study: 17320026
Drug: Surrogate markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrogate markers for PMO treatments
Study: 3306292
Drug: Org OD
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD 14 (2.5 mg/day for 12 weeks)
Study: 28803691
Drug: Topical lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lavender oil ointment
Study: 28803691
Drug: Night wrist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night wrist orthotic and placebo ointment
Study: 27243899
Drug: Mobility Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobility Program (MP) - assisted ambulation up to twice daily with a behavioral strategy to encourage mobility.
Study: 27243899
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care (UC) - received twice-daily visits.
Study: 23472071
Drug: 1% vaginal
Normalized name: Mycelex 1% Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% vaginal tenofovir gel
Study: 12809830
Drug: Rifaximin 600
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 600 mg per day
Study: 12809830
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg per day
Study: 12809830
Drug: Rifaximin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (both doses)
Study: 1346268
Drug: Epanolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epanolol (200 mg daily)
Study: 7899788
Drug: Ivermectin administration
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin administration
Study: 25147013
Drug: Balneohydrotherapy (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneohydrotherapy (18 days of treatment including Kneipp therapy, walking in a mineral water pool, massage, and bathing in a mineral water tub)
Study: 8925544
Drug: Heparan sulphate
Normalized name: Heparan sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulphate (100 mg/day for 3-4 months)
Study: 6418441
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (2 mg 4-times daily)
Study: 26363305
Drug: Six sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six sessions of cognitive therapy
Study: 17516769
Drug: Motivational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational therapy
Study: 20304772
Drug: Airway clearance
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airway clearance therapy (ACT)
Study: 10727589
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 or 2 mg/kg body weight)
Study: 9403265
Drug: Povidone-iodine sugar
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine sugar ointment (P-1, P-2, P-3)
Study: 9403265
Drug: Povidone-iodine sugar
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine sugar ointment (P-3)
Study: 9403265
Drug: Povidone-iodine sugar
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine sugar ointment (P-1, P-2)
Study: 30290905
Drug: Thalidomide (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200-400 mg, orally on days 1-28) during induction and maintenance therapy.
Study: 30290905
Drug: Thalidomide maintenance
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide maintenance therapy (50 mg, orally, daily).
Study: 30290905
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 × 10^6 international units, subcutaneously, three times weekly) during maintenance therapy.
Study: 22801271
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (national made atorvastatin)
Study: 22801271
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (imported atorvastatin)
Study: 15735110
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient supplement (DMM)
Study: 15735110
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo supplement (P)
Study: 15735110
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplement 1 day of the week and placebo on other days (WMM)
Study: 15735110
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplement (DI)
Study: 8916595
Drug: Pilocarpine 1%
Normalized name: PILOCARPINE 1% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 1% and Clonidine 0.125% combination
Study: 28319550
Drug: Basal infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal infusion (8 mL/h)
Study: 28319550
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses (24 mL every 3 hours for a total of 2 bolus doses)
Study: 24047421
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg/day (N=25)
Study: 24047421
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day (N=24)
Study: 21861972
Drug: Selective laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective laser trabeculoplasty (performed a mean of 8.3 ± 4.1 days before injection)
Study: 21861972
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide injection (control group)
Study: 9928687
Drug: Ketorolac (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (60 mg intramuscular injection)
Study: 9928687
Drug: Meperidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (100 to 150 mg intramuscular injection based on weight)
Study: 7233551
Drug: Niridazole (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niridazole (7-day treatment)
Study: 7233551
Drug: Praziquantel (1-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (1-day treatment, 2 x 30 mg per kg)
Study: 30085011
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug use during one month prior to recruitment
Study: 28452603
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during surgery (Group M)
Study: 28452603
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (Group M)
Study: 12562741
Drug: Dialectical behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical behaviour therapy (DBT) for 12 months
Study: 16903592
Drug: Rolling needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolling needle therapy at the Urinary Bladder Channel line 1 and 2 and the Governor Vessel for 4 weeks
Study: 16903592
Drug: Clonopin 4-6
Normalized name: Klonopin
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonopin 4-6 mg for 4 weeks
Study: 16903592
Drug: Rolling needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolling needle therapy after 3 months follow-up
Study: 14684393
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg 3 times daily)
Study: 11339779
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (SA) with 50 mg of 1% lidocaine
Study: 10423596
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine after overnight fast
Study: 10423596
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine after low-fat breakfast
Study: 10423596
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine after high-fat breakfast
Study: 10423596
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ebastine after overnight fast
Study: 10423596
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ebastine after high-fat breakfast
Study: 3295883
Drug: Adenosine (0.104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (0.104 +/- 0.024 mg/kg)
Study: 3295883
Drug: Verapamil (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (8.4 +/- 3.4 mg IV)
Study: 29073351
Drug: Belimumab at
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab at 10 mg/kg intravenously
Study: 23899530
Drug: Sunitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib at 37.5mg daily until progression or a maximum of 6 months (arm B)
Study: 20839434
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg) intravenously injected before 1 hour of cement injection
Study: 20839434
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 mL) intravenously injected
Study: 20839434
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg) intravenously injected
Study: 15837829
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (375 mL; 39 grams alcohol)
Study: 15837829
Drug: Beer (1125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (1125 mL; 41 grams alcohol)
Study: 15837829
Drug: De-alcoholized red
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-alcoholized red wine (375 mL)
Study: 10467610
Drug: TPN as
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN as adjunct of medical therapy (Group I)
Study: 7592151
Drug: Stimulus-choice procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus-choice procedure with two treatments based on Premack's principle
Study: 6794419
Drug: Metoprolol Durules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol Durules administered once daily at a daily dosage of 200 mg
Study: 6794419
Drug: Metoprolol tablets
Normalized name: metoprolol Oral Tablet
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tablets administered twice daily at a daily dosage of 200 mg
Study: 29709606
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) combined with antimicrobial photodynamic therapy (aPDT)
Study: 22437556
Drug: Rice-based lunch
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based lunch meals fortified with low-iron (6.25 mg) micronutrients
Study: 22437556
Drug: Rice-based lunch
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based lunch meals fortified with high-iron (12.5 mg) micronutrients
Study: 11155731
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day treatment
Study: 11155731
Drug: 14 day
Normalized name: Ponvory 14 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day treatment
Study: 8684102
Drug: Atovaquone 1000
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atovaquone 1000 mg daily and proguanil 400 mg daily for 3 days
Study: 8684102
Drug: Amodiaquine 600
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine 600 mg on admission, 600 mg 24 h later, and 300 mg after a further 24 h
Study: 14621737
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (group B)
Study: 14621737
Drug: Low-dose CyA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CyA plus azathioprine (group C)
Study: 3970747
Drug: Antibiotics (penicillinase-resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (penicillinase-resistant penicillin or erythromycin)
Study: 3970747
Drug: Penicillinase-resistant antibiotic
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillinase-resistant antibiotic
Study: 25863559
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg)
Study: 25863559
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) plus ribavirin
Study: 19040034
Drug: MF59-adjuvanted influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted influenza subunit vaccine (FLUAD)
Study: 19040034
Drug: Conventional non-adjuvanted
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-adjuvanted influenza subunit vaccine (Agrippal)
Study: 10475285
Drug: Amiodarone (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (3.4 g over 5 days or 2.2 g over 24 hours)
Study: 2771867
Drug: flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: flunitrazepam 1 mg
Study: 8091361
Drug: triazolam 0.25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam 0.25 mg
Study: 6147843
Drug: lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam 1 mg
Study: 29790581
Drug: PUR0200 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR0200 3 μg
Study: 29790581
Drug: PUR0200 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR0200 6 μg
Study: 29790581
Drug: PUR0200 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR0200 9 μg
Study: 29790581
Drug: Tiotropium HH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium HH 18 μg
Study: 8187256
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 5.0 mg.kg‐1
Study: 989091
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous heparin sodium therapy
Study: 989091
Drug: Intermittent (four‐hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent (four‐hourly bolus) heparin therapy
Study: 29283470
Drug: REMD‐477 (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMD‐477 (70 mg dose)
Study: 27331913
Drug: Caffeine-polyphenol supplement
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine-polyphenol supplement
Study: 24269575
Drug: Duloxetine (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (combined serotonin-norepinephrine reuptake inhibitor)
Study: 10877010
Drug: Caffeine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (single oral dose)
Study: 21061756
Drug: Methylaminolevulinate (MAL)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL) 80 mg/g without occlusion followed by 25 J/cm2 red light exposure
Study: 21061756
Drug: Methylaminolevulinate (MAL)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL) 80 mg/g with occlusion followed by 25 J/cm2 red light exposure
Study: 21061756
Drug: Methylaminolevulinate (MAL)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL) 80 mg/g without occlusion followed by 37 J/cm2 red light exposure
Study: 21061756
Drug: Methylaminolevulinate (MAL)
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylaminolevulinate (MAL) 80 mg/g with occlusion followed by 37 J/cm2 red light exposure
Study: 17426414
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (paroxetine or clomipramine)
Study: 9580313
Drug: 0.9 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Study: 9580313
Drug: 1.8 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Study: 9580313
Drug: 3.6 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Study: 23537017
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg total)
Study: 18281352
Drug: Cumulative weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative weekly breastfeeding duration by 13 weeks
Study: 15271868
Drug: Half-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose triptorelin (1.87 mg)
Study: 15271868
Drug: Full-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose triptorelin (3.75 mg)
Study: 10858349
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (2.5 mg/kg twice a day)
Study: 10858349
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B capsules (500 mg orally four times a day)
Study: 20142307
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sleep deprivation and morphine
Study: 20142307
Drug: Buprenorphine on
Normalized name: Buprenorphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine on dosing day with sleep deprivation
Study: 20142307
Drug: Alternate-day buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day buprenorphine dosing
Study: 18664888
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments for PTSD
Study: 18664888
Drug: Psychosocial treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatments for PTSD targeting combat-related trauma
Study: 16599101
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate tablet (20 mg)
Study: 12166540
Drug: Budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 160/4.5 microg, two inhalations twice daily (n=390)
Study: 12166540
Drug: Budesonide plus
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide plus formoterol administered via separate inhalers (n=190)
Study: 10604851
Drug: Air inhalation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air inhalation (control)
Study: 1714669
Drug: Bonnecor (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonnecor (2 x 0.1 to 1 x 0.3 mg/kg body weight)
Study: 27918733
Drug: Basic information
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic information given verbally with details of operative procedures and recovery, and by watching a movie on single implant surgery (movie group)
Study: 23958023
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplement (200 g/d)